Table 5.
Comparison of Observed Sustained Virologic Response Among Patients With Available Sustained Virologic Response Data (n = 15,884) and Combined Observed or Imputed Sustained Virologic Response Among All Patients Who Initiated Antiviral Treatment (n = 17,487)
| Observed SVR, % (95% CI) (n = 15,884) | Observed SVR or Imputed SVRa for patients missing SVR data, % (95% CI) (n = 17,301) | SVR assuming all patients with missing SVR data did not achieve SVR, % (95% CI) (n = 17,487) | |
|---|---|---|---|
| All patients | 90.7 (90.2–91.1) | 90.0 (90–91) | 82.4 (81.8–82.9) |
| Genotype 1 | 92.8 (92.3–93.2) | 92.2 (92–93) | 84.6 (84.0–85.2) |
| LDV/SOF | 92.9 (92.2–93.3) | 93 (92–93) | 84.5 (83.7–85.3) |
| LDV/SOF+RIBA | 92.0 (90.9–93.0) | 92 (90–93) | 85.5 (84.1–86.8) |
| PrOD | 94.9 (92.9–96.3) | 94 (92–96) | 86.1 (83.5–88.3) |
| PrOD+RIBA | 92.5 (91.3–93.5) | 91 (90–92) | 83.2 (81.6–84.6) |
| Genotype 2 | |||
| SOF+RIBA | 86.2 (84.6–87.7) | 85 (84–87) | 77.2 (75.4–79.0) |
| Genotype 3 | 74.8 (72.2–77.3) | 73.9 (71–77) | 66.3 (63.6–68.9) |
| LDV/SOF+RIBA | 77.9 (73.1–82.0) | 77 (73–82) | 68.4 (63.6–72.8) |
| SOF+PEG+RIBA | 87.0 (80.0–91.8) | 86 (80–92) | 81.4 (74.0–87.1) |
| SOF+RIBA | 70.6 (66.9–74.1) | 70 (66–73) | 62.2 (58.6–65.7) |
| Genotype 4 | 89.6 (82.8–93.9) | 86.9 (81–93) | 83.0 (75.6–88.5) |
| LDV/SOF±RIBA | 87.6 (79.3 –92.9) | 86 (78–93) | 82.5 (73.8–88.8) |
| PrOD±RIBA | 96.4 (76.3 –99.5) | 90 (78–100) | 84.3 (66.3–93.7) |
a
Imputed by multiple imputation using a logistic regression model that included duration of treatment together with 24 baseline patient characteristics shown in Table 1. The number of patients is slightly less than 17,487 due to missing data in the characteristics used to impute SVR.